MARKETS / PLSH
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Panacea Life Sciences Holdings, Inc. PLSH
10 fiscal years on record · USD · FY2023 reported · SEC filings only
Growth
USD 2.4M
Revenue, FY2023 · full 10-year series below
Revenue $M
Net income $M
FY2023 · Revenue 2.4 · Net income -8.0
Compound annual growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−336 cents
lost on every revenue dollar
Operating margin
Net margin
FY2023 · Operating -232.5% · Net -336.1%
ROE
FY2022 · ROE -368.8%
The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | · | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −0.48 | −0.62 | −0.27 | −0.31 | −0.30 | −0.91 | −0.91 | −0.08 | −0.70 | −0.02 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | −368.8 | −69.3 | −56.1 | −235.3 | · | · | −227.9 | · | −648.0 |
| Shares out B | 0.02 | 0.01 | 0.01 | 0.02 | 0.04 | 0.01 | 0.00 | 0.03 | 0.00 | 0.02 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 46 reconciliationsAUDITED
Reconciled in 10 of 19 fiscal years. 49 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onnot stated in the filings
Incorporated inNevada
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2014